πŸ‡ΊπŸ‡Έ FDA
Patent

US 8691831

Heterocyclic aspartyl protease inhibitors

granted A61KA61K31/4168A61K31/4178

Quick answer

US patent 8691831 (Heterocyclic aspartyl protease inhibitors) held by Pharmacopeia Drug Discovery, Inc. expires Mon Apr 03 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Pharmacopeia Drug Discovery, Inc.
Grant date
Tue Apr 08 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 03 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K31/4168, A61K31/4178, A61P, A61P25/00